From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials

This publication has 18 references indexed in Scilit:

• Teaching old drugs new tricks
  Trends in Neurosciences, 2002
• Genetically engineered mouse models of neurodegenerative diseases
  Nature Neuroscience, 2002
• Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice
  Proceedings of the National Academy of Sciences, 2002
• Modelling neurodegenerative diseases in Drosophila: a fruitful approach?
  Nature Reviews Neuroscience, 2002
• Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients
  Human Molecular Genetics, 2001
• Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
  Proceedings of the National Academy of Sciences, 2001
• Huntington's disease: the challenge for cell biologists
  Trends in Cell Biology, 2000
• Animal models of spinal muscular atrophy
  Human Molecular Genetics, 2000
• Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions
  Molecular Medicine Today, 1997
• Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis
  Annals of Neurology, 1996